AR110159A2 - ANTI-TSLP HUMAN ANTIBODY (THYMPIC STROMAL LYMPHOPOYETIN), AND ITS EMPLOYMENT IN THE TREATMENT OF INFLAMMATORY AFFECTION RELATED TO TSLP - Google Patents

ANTI-TSLP HUMAN ANTIBODY (THYMPIC STROMAL LYMPHOPOYETIN), AND ITS EMPLOYMENT IN THE TREATMENT OF INFLAMMATORY AFFECTION RELATED TO TSLP

Info

Publication number
AR110159A2
AR110159A2 ARP170103113A ARP170103113A AR110159A2 AR 110159 A2 AR110159 A2 AR 110159A2 AR P170103113 A ARP170103113 A AR P170103113A AR P170103113 A ARP170103113 A AR P170103113A AR 110159 A2 AR110159 A2 AR 110159A2
Authority
AR
Argentina
Prior art keywords
tslp
treatment
thympic
lymphopoyetin
stromal
Prior art date
Application number
ARP170103113A
Other languages
Spanish (es)
Inventor
Christopher Mehlin
Bo Yoon
P - Smothers James F Rin
Michael R Comeau
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR110159A2 publication Critical patent/AR110159A2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente publicación proporciona las composiciones y métodos relacionados con proteínas de unión de antígenos que se unen a estroma linfopoyetina tímica (TSLP) humana, incluyendo anticuerpos. En particulares realizaciones, la divulgación brinda anticuerpos plenamente humano, humanizado y anti-TSLP quimérico y derivados de estos anticuerpos. Esta divulgación prevé además métodos de tratamiento y prevención de trastornos fibróticos relacionados con la TSLP.The present publication provides compositions and methods related to antigen binding proteins that bind to human thymic lymphopoietin stroma (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of these antibodies. This disclosure also provides methods of treatment and prevention of fibrotic disorders related to TSLP.

ARP170103113A 2007-09-10 2017-11-08 ANTI-TSLP HUMAN ANTIBODY (THYMPIC STROMAL LYMPHOPOYETIN), AND ITS EMPLOYMENT IN THE TREATMENT OF INFLAMMATORY AFFECTION RELATED TO TSLP AR110159A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97117807P 2007-09-10 2007-09-10

Publications (1)

Publication Number Publication Date
AR110159A2 true AR110159A2 (en) 2019-02-27

Family

ID=51583876

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103113A AR110159A2 (en) 2007-09-10 2017-11-08 ANTI-TSLP HUMAN ANTIBODY (THYMPIC STROMAL LYMPHOPOYETIN), AND ITS EMPLOYMENT IN THE TREATMENT OF INFLAMMATORY AFFECTION RELATED TO TSLP

Country Status (2)

Country Link
AR (1) AR110159A2 (en)
UA (1) UA100531C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113501878B (en) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 Antibodies against human TSLP and uses thereof
CN117209603B (en) * 2021-12-02 2024-02-27 北京东方百泰生物科技股份有限公司 anti-TSLP monoclonal antibody, antigen binding fragment thereof and application thereof

Also Published As

Publication number Publication date
UA100531C2 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
CR20150095A (en) PROTEINS OF UNION TO ANTIGEN CAPABLE OF JOINING THYMPIC STROMATIC LYMPHOPOYETIN
CY1123145T1 (en) ANTI-CD40 ANTIBODIES
CY1120887T1 (en) ANTIBODIES THAT BIND IL-4 AND / OR IL-13 AND THEIR USES
CL2008003361A1 (en) Monoclonal antibodies that bind to hgm-csf and the average compositions that comprise them.
CR20110152A (en) ANTI-IL-13 MODIFIED ANTIBODIES, COMPOSITIONS, METHODS AND USES
EA201370081A1 (en) ANTIBODIES TO CD48 AND THEIR APPLICATION
EA200870050A1 (en) ANTI-IL-17-ANTIBODIES
AR076655A1 (en) COMPOSITIONS AND METHODS FOR ANTIBODIES GOING TO THE COMPLEMENT PROTEIN C3B
PE20060376A1 (en) HUMANIZED OR CHEMERIC MONOCLONAL ANTIBODY AS AN INHIBITOR OF hIL-3
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
EA202092884A1 (en) COMPOSITIONS WITH HIGH ANTIBODY CONCENTRATION
AR078650A1 (en) ANTIBODY OF UNION TO IL-1 BETA
PE20081186A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALLERGIC DISEASES
PE20090294A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ANTAGONIST OF FACTOR D AND ITS USE IN THE TREATMENT OF EYE CONDITIONS
NO20084650L (en) Modified humanized anti-interleukin-18 antibodies
MX337290B (en) NON-CROSS-REACTIVE ANTI IgG ANTIBODIES.
EA201590208A1 (en) CAR ACTIVITY STRENGTHENING BY CAR BY JOINT INTRODUCTION OF BISPECIFIC ANTIBODIES
EA200802168A1 (en) HUMANIZED ANTIBODY TO C-KIT
AR059867A1 (en) ANTIBODIES FOR HTSLP
AU2009260320A8 (en) Antibodies to IL-6 and their uses
RS54795B1 (en) Anti-her3 antibodies and uses thereof
EA201290589A1 (en) CD127-BINDING PROTEINS
ATE553778T1 (en) ANTIBODIES SPECIFIC TO HUMAN HEPCIDIN
MX2009005103A (en) Anti-idiotype conjugate and its use as a standard in an immunassay.
CY1123519T1 (en) HUMAN IL-ẞ NEUTRALIZING MONOCLONAL ANTIBODIES